Abstract 4381: High efficacy of T-LAK cell-originated protein kinase inhibitor in acute myeloid leukemia with FLT3-ITD mutation

The internal tandem duplication (FLT3-ITD) a gain-of-function mutation of FLT3, is associated with poor outcome in acute myeloid leukemia (AML). The use of FLT3 inhibitors currently undergoing clinical investigation has not yet improved overall survival. Therefore, novel therapies are needed. T-LAK cell-originated protein kinase (TOPK), a serine-threonine protein kinase, is highly expressed and associated with an aggressive cancer phenotype, but is hardly detectable in normal tissues. Here, we investigate TOPK in AML and demonstrate that it is highly expressed in most AML cell lines and some primary blasts, but is not detected in CD34+ cells of healthy donors. MV4-11 and U937 cells transfected with TOPK-siRNA showed significant decrease in cell viability (∼70%, P

Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Alachkar, H., Mutonga, M., Park, J.-H., Malnassy, G., Woods, A., Raca, G., Odenike, O. M., Takamatsu, N., Miyamoto, T., Hisada, S., Matsuo, Y., Stock, W., Nakamura, Y. Tags: Experimental and Molecular Therapeutics Source Type: research